Trial Profile

A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 16 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Reldesemtiv (Primary)
Indications Amyotrophic lateral sclerosis
Focus Adverse reactions; Registrational
Acronyms COURAGE-ALS OLE
Sponsors Cytokinetics

Most Recent Events

01 Jul 2023 This trial has been completed in Belgium, according to European Clinical Trials Database record.
12 Apr 2023 Status changed from recruiting to discontinued.
31 Mar 2023 According to a Cytokinetics media release, Cytokinetics plans to discontinue treatment with reldesemtiv in all patients including those in this open-label extension study, COURAGE-ALS OLE.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com